Startup Deep Dive : Gennova Biopharmaceuticals — India’s first mRNA vaccine maker earns its keep elsewhere

In June 2022, a Pune company that most Indians had never heard of did something neither Serum Institute nor Bharat Biotech had managed: it registered India’s first home-grown mRNA vaccine, GEMCOVAC-19, only the third mRNA COVID-19 shot cleared anywhere in the world at that point. Yet four years on, that same company — Gennova Biopharmaceuticals — posted FY24 revenue of about ₹422 crore ($44 million, at $1 ≈ ₹96.0), and almost none of it came from the vaccine that made its name.

That is the paradox worth sitting with. Gennova is celebrated for a pandemic product it can barely sell today, while it quietly earns its keep from a portfolio of biosimilars that rarely makes the news. In July 2026, its listed parent, Emcure Pharmaceuticals, paid ₹231.87 crore to buy out the last minority shareholders and take Gennova to 100% ownership — a transaction that valued the whole biotech at roughly ₹1,924 crore. This is the story of how a quiet contract-biology outfit became a national symbol, and why the symbol and the business are two very different things.

Quick facts

What Gennova actually does

Gennova Biopharmaceuticals is a Pune-based biotechnology company that makes complex, protein-based medicines and, more recently, mRNA vaccines. It is not a household consumer brand; it sells to hospitals, doctors and government programmes, largely through the distribution muscle of its parent, Emcure Pharmaceuticals. Its registered office sits in the Hinjawadi IT-BT park in Pune (MCA/Tofler record).

• Core business: a portfolio of roughly 8–9 marketed biosimilars and biotherapeutics across oncology, cardiovascular, neurology and nephrology, sold in India and emerging markets (CRISIL rating rationale, October 2025).
• Vaccines: GEMCOVAC-19, described across multiple outlets as India’s first indigenously developed mRNA COVID-19 vaccine, and GEMCOVAC-OM, an Omicron-specific booster (Business Standard and Forbes India, 2022; PharmaJet, 2023).
• Manufacturing: an mRNA facility with API capacity company-stated at about 500 million doses a year, expandable, and fill-finish capacity of about 200 million doses a year (Forbes India, 2022).
• Ownership model: a captive R&D-and-manufacturing arm of Emcure rather than a standalone commercial company — a structure that shapes almost everything about its finances.

The origin: a scientist from the NIH and a Pune pharma family

The legal entity behind Gennova was incorporated on 19 June 2001, according to its Ministry of Corporate Affairs record. But the company as it exists today really began in 2006, when Dr Sanjay Singh took over as its founder-CEO. Singh was not a typical Indian pharma executive. He had headed the Antigen Research Section at the Malaria Vaccine Development Unit of the US National Institute of Allergy and Infectious Diseases, part of the NIH, and holds a PhD in biochemistry from the Central Drug Research Institute in Lucknow (ICGEB profile; Emcure leadership page).

The other half of the story is the family that backed him. Gennova was set up as a subsidiary of Emcure Pharmaceuticals, the Pune drugmaker founded in 1981 by Satish Mehta (Forbes India, 2022). The bet was unusual for Indian pharma at the time: instead of chasing generic small-molecule pills, Gennova would build the harder, costlier capability of biologics — medicines grown in living cells rather than mixed in a reactor. Over the following years that patience produced a run of commercialised biotherapeutics, and, crucially, the in-house know-how in nucleic acids and protein engineering that would matter enormously when a coronavirus arrived in 2020.

The struggle years: embargoes, a lawsuit and a vanishing market

Gennova’s most visible achievement was almost strangled at birth. When it raced to build GEMCOVAC-19 during the pandemic, the company ran into a US embargo on the export of key raw materials at the peak of global demand — including the enzymes needed to make mRNA active ingredient. It survived by leaning on its parent: Emcure supplied raw materials and reagents that Gennova could no longer import (Forbes India, 2022). For a company being celebrated as a symbol of Indian self-reliance, the near-miss was pointed.

The second setback was legal, and it went to the heart of the science. The mRNA platform behind GEMCOVAC was co-developed with HDT Bio Corp, a Seattle biotech whose self-amplifying RNA and LION lipid-nanoparticle delivery technology gave the vaccine its ability to work at low doses and survive at ordinary fridge temperatures of 2–8°C (CEPI; HDT Bio; Petrie-Flom Center, Harvard Law, 2022). In March 2022, HDT Bio sued Emcure and Gennova in a US court, alleging that they were presenting the technology as their own and had sought Indian patents on it (Business Standard, March 2022). The dispute was later put on a commercial footing: CRISIL’s October 2025 report records that Gennova acquired licensing rights from HDT Bio Corp for about ₹150 crore, a payment that materially raised its debt.

The third setback was the cruellest, because it followed success. Once the pandemic emergency faded, demand for COVID-19 vaccines collapsed, and by late 2022 commentators were openly asking whether GEMCOVAC-19 had any commercial relevance left (Forbes India, 2022). Gennova had built a symbol; it now had to prove it still had a business.

The turning point: 29 June 2022

The single event that changed how India saw Gennova came on 29 June 2022, when the company announced that the Drugs Controller General of India had granted GEMCOVAC-19 emergency use authorisation for adults (Business Standard and medthority, 2022). It was a two-dose vaccine given intramuscularly 28 days apart, and unlike the Pfizer-BioNTech and Moderna shots that needed sub-zero cold chains, it could be stored at ordinary refrigerator temperatures — a decisive advantage for a country with patchy cold-chain infrastructure.

Consider the two sides of that moment. Before it, India had no mRNA vaccine of its own and depended entirely on foreign platforms for the technology; multiple outlets described GEMCOVAC-19 as the first developed in India and only the third mRNA COVID-19 vaccine authorised anywhere in the world at the time (Business Standard; Gulf News, 2022). After it, Gennova said it was ready to roll out 70 lakh (7 million) doses and could produce 40–50 lakh doses a month at peak (Outlook India and Business Standard, 2022). Gennova followed up with GEMCOVAC-OM, an Omicron-specific booster that later received emergency use authorisation and was notable for a needle-free intradermal delivery route using PharmaJet’s device (PharmaJet, 2023). The science was validated. The market, unfortunately, was already shrinking.

The money behind it: grants, a parent and no venture capital

Gennova is one of the more instructive funding stories in Indian biotech precisely because it did not follow the venture-capital script. There is no Series A, no unicorn valuation announcement, no investor cap table to parse. Its capital came from three places:

• Government grants: an initial ₹25 crore seed grant from the Department of Biotechnology under the Mission COVID Suraksha programme in June 2020, followed by roughly ₹100 crore more after Phase 1 trials (Forbes India, 2022).
• Parent support: the balance of the vaccine programme was funded by Emcure and internal accruals rather than external investors (Forbes India, 2022). CRISIL’s October 2025 rating explicitly rests on “the strong operational, managerial, technical and financial support” Gennova receives from Emcure.
• The buyout, not a raise: the defining recent transaction moved ownership rather than adding capital. On 21 July 2026 Emcure completed the purchase of the final 12.05% stake — 663,865 shares held by individual shareholders — for ₹231.87 crore, taking its holding from 87.95% to 100% (Emcure exchange disclosure, reported by ScanX and Whalesbook, July 2026).
• Implied valuation: that price for 12.05% implies an equity value of roughly ₹1,924 crore for the whole company. Treat it as a derived, single-transaction figure rather than an audited market valuation — it is the best public benchmark available, but it is one buyer paying one price.

How it makes money

The gap between Gennova’s fame and its finances closes once you see where the revenue actually comes from. The money engine is not the vaccine; it is the biosimilar and biotherapeutics portfolio.

• Product sales: revenue is driven by a portfolio of roughly 8–9 marketed biologics across oncology, cardiovascular, neurology and nephrology, sold in India and emerging markets (CRISIL, October 2025).
• Distribution leverage: Gennova reaches the market largely through Emcure’s sales and distribution network rather than building a large independent commercial force — part of why the parent’s control matters.
• Margin profile: profitability sits in the manufacturing and formulation of complex biologics. CARE Ratings recorded a PBILDT (operating) margin of 26.10% in FY23, up from 20.31% in FY22; CRISIL put the FY25 operating margin lower, at 18.3%, after a difficult year.
• The part people get wrong: outsiders assume the mRNA vaccine is the business. It is the brand. The recurring cash comes from unglamorous biosimilars, and the vaccine platform is closer to a strategic option on future pandemics and pipeline products than a current revenue line.
• Working capital: the business is working-capital intensive, with CRISIL noting gross current assets of about 262 days in its October 2025 assessment — a reminder that biologics tie up cash.

The numbers: four years of revenue and profit

Because Gennova is unlisted, its figures surface through credit-rating agencies and, since July 2026, through its parent’s exchange filings. The picture is one of steady top-line growth interrupted by a sharp, explained dip in profit.

The FY25 loss is the most important data point, and CRISIL is explicit about the cause: revenue grew only about 5% year-on-year because of the patent expiry of a key molecule, while the roughly ₹150 crore acquisition of HDT Bio licensing rights pushed total debt up to about ₹346 crore (from ₹175 crore in FY24) and lifted the debt-to-equity ratio to 1.49x. Net worth eased to about ₹233 crore in FY25 from ₹245 crore. Revenue then recovered to ₹491.74 crore in FY26 and the company returned to a small profit of ₹5.4 crore (Emcure exchange disclosure, July 2026), with first-quarter FY26 revenue of about ₹99 crore already reported by CRISIL.

Where the money comes from

Gennova does not publish a segment-by-segment revenue split, so the honest answer is that a precise breakdown by product or geography is not in the public record. What the filings do let us say, attributed and dated:

• By product type: the durable revenue base is biosimilars and biotherapeutics across four therapy areas, not the COVID vaccine (CRISIL, October 2025).
• By geography: sales run through India and emerging markets via Emcure’s network (CRISIL, October 2025); a country-level split is not disclosed.
• The surprise: the product Gennova is famous for — GEMCOVAC — is not what pays the bills. The single molecule whose patent expired mattered enough to turn a profitable FY24 into a loss-making FY25, which tells you how concentrated the earnings base still is.
• The parent contrast: Emcure, the listed parent, reported consolidated FY25 revenue of about ₹7,896 crore and profit of about ₹707 crore (Emcure results coverage), against FY24 revenue of about ₹6,658 crore. Gennova, at roughly ₹432–492 crore of revenue, is a strategically important but financially small slice of that whole.

The risks

Gennova’s risks are unusually concrete, and several are disclosed through its own rating documents.

• Product concentration: FY25 showed that the loss of exclusivity on a single key molecule can flip the company from profit to loss (CRISIL, October 2025). A narrow earnings base magnifies every patent cliff.
• Rising leverage: total debt roughly doubled to about ₹346 crore in FY25 and debt-to-equity hit 1.49x, driven by the ₹150 crore HDT Bio licensing payment (CRISIL). Higher debt narrows the margin for error if a launch slips.
• Working-capital intensity: gross current assets of about 262 days (CRISIL, October 2025) mean a lot of cash is locked in inventory and receivables, a structural feature of biologics manufacturing.
• Intellectual-property exposure: the HDT Bio litigation over the mRNA platform (filed March 2022, per Business Standard) showed how dependent Gennova’s flagship technology was on a foreign partner — a risk the ₹150 crore licensing deal was meant to contain rather than eliminate.
• A vanished vaccine market: post-pandemic demand for COVID-19 vaccines has collapsed (Forbes India, 2022), so the platform that created the brand contributes little recurring revenue and needs a fresh pipeline to justify itself.
• Dependence on the parent: CRISIL’s investment-grade rating leans heavily on Emcure’s financial and managerial support. That is a strength today and a concentration risk if the parent’s priorities ever shift.

The takeaway

The transferable lesson from Gennova is that a breakthrough and a business are not the same thing, and confusing them is expensive. Gennova built something genuinely hard — the first mRNA vaccine developed in India, on a self-amplifying platform that worked at fridge temperature — and it earned every headline. But headlines do not amortise a ₹150 crore licensing payment, and a symbol does not cover a patent cliff. The company that survives on the other side of the applause is the one that kept a boring, cash-generating biosimilars business running underneath the famous one. For any founder chasing a moonshot, Gennova’s record is a quiet argument for owning both: the moonshot that gets you noticed, and the base business that keeps you alive long enough to take the next shot.

Frequently asked questions

Is Gennova Biopharmaceuticals a listed company?

No. Gennova is a private, unlisted company. Since 21 July 2026 it has been a 100% subsidiary of Emcure Pharmaceuticals, which is itself listed on the NSE and BSE. Emcure lifted its stake from 87.95% to 100% by buying the remaining 12.05% for ₹231.87 crore (Emcure exchange disclosure, July 2026).

Did Gennova really make India’s first mRNA vaccine?

Yes, according to multiple independent reports. GEMCOVAC-19 received emergency use authorisation from the DCGI on 29 June 2022 and was described by outlets including Business Standard and Gulf News as India’s first indigenously developed mRNA COVID-19 vaccine, and among the first three mRNA COVID vaccines authorised worldwide at the time.

How much money does Gennova make?

Gennova reported turnover of ₹491.74 crore and a profit after tax of ₹5.4 crore in FY26 (Emcure filing, July 2026). CRISIL put its operating income at about ₹432 crore in FY25, a year in which it recorded a loss of about ₹12 crore after the patent expiry of a key molecule.

Who founded and runs Gennova?

Dr Sanjay Singh has been the founder-CEO since 2006. Before Gennova he headed the Antigen Research Section at the US NIH’s malaria vaccine unit and holds a PhD from the Central Drug Research Institute, Lucknow (ICGEB; Emcure leadership page). The company is part of the Emcure group founded by Satish Mehta.

What is Gennova worth?

The most recent public benchmark is Emcure’s July 2026 purchase of a 12.05% stake for ₹231.87 crore, which implies an equity value of roughly ₹1,924 crore for the whole company. This is a figure derived from one transaction rather than an audited or market valuation, so it should be read as indicative.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• CRISIL Ratings, rating rationale for Gennova Biopharmaceuticals Limited — October 2025 (FY24/FY25 operating income, PAT, debt, net worth, margins, HDT Bio licensing, Emcure support).
• CARE Ratings, press release on Gennova Biopharmaceuticals Limited — January 2024 (FY22 and FY23 PAT and PBILDT margins).
• Emcure Pharmaceuticals exchange disclosure on acquisition of the residual Gennova stake, reported by ScanX and Whalesbook — July 2026 (12.05% for ₹231.87 crore; FY24–FY26 turnover and FY26 PAT; 100% ownership).
• Tofler / Ministry of Corporate Affairs company record for Gennova Biopharmaceuticals Limited — accessed September 2026 (incorporation date, CIN, registered office, directors, paid-up capital).
• Forbes India, “Gennova Biopharmaceuticals has become India’s first mRNA Covid-19 vaccine maker” — 2022 (DBT grants, US raw-material embargo, capacity, post-pandemic relevance).
• Business Standard, coverage of GEMCOVAC-19 authorisation and doses — June 2022; and “Gennova’s mRNA vaccine in legal storm after HDT Bio Corp sues Emcure” — March 2022.
• Outlook India, “Gennova Biopharmaceuticals is ready to roll out 70 lakh doses of its Gemcovac-19 vaccine” — 2022.
• Gulf News, “India’s 1st indigenously developed mRNA vaccine against Covid gets DCGI approval” — June 2022.
• PharmaJet press release on GEMCOVAC-OM needle-free Omicron booster EUA — 2023.
• CEPI and HDT Bio Corp materials, and Petrie-Flom Center (Harvard Law) analysis of HDT Bio v. Emcure — 2022 (self-amplifying RNA and LION platform, IP dispute).
• ICGEB profile of Dr Sanjay Singh and Emcure leadership page — accessed September 2026 (founder background, CEO since 2006).
• Emcure Pharmaceuticals IPO and FY24/FY25 results coverage (Chittorgarh, IndMoney, Screener) — 2024–2025 (parent revenue, profit, IPO July 2024).

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.